Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo

Fig. 4

Cirsiliol binds with TYK2 and inhibits the kinase activity. a Computational docking model between cirsiliol and TYK2. b The detailed binding site of cirsiliol on TYK2. c Upper panel: the binding ability of cirsiliol on endogenic TYK2 in vitro, obtained via pull down assay. Down panel: the binding ability of cirsiliol to recombinant TYK2 protein. d The change of affinity response intensity with the passage of time. -60 to 0 s was set as the time before inject cirsiliol solution; 0–120 s was set as contact time between cirsiliol and TYK2; 120–180 s was set as dissociation time. e The variation of response intensity with the increase of cirsiliol concentration. f Upper panel: cirsiliol binding ability with mutant TYK2. Down panel: the protein level of TYK2 in 293 T cell line. 1A (V981A), 1’A (P982A), 2A (double mutant), WT: wild type. g Kinase assay performed with cirsiliol and TYK2. h p-STAT3 inhibition analyzed by ImageJ in three independent assays (n = 3, *p < 0.05, **p < 0.01). Student’s unpaired t-test in (h). KD, dissociation constant

Back to article page